Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

被引：1

作者：

Wang, Michael ^{[1
]}

Jurczak, Wojciech ^{[2
]}

Trneny, Marek ^{[3
]}

Belada, David ^{[4
]}

Wrobel, Tomasz ^{[5
]}

Ghosh, Nilanjan ^{[6
]}

Keating, Mary-Margaret ^{[7
]}

van Meerten, Tom ^{[8
]}

Fernandez Alvarez, Ruben ^{[9
]}

von Keudell, Gottfried ^{[10
]}

Thieblemont, Catherine ^{[11
]}

Peyrade, Frederic ^{[12
]}

Andre, Marc ^{[13
]}

Hoffmann, Marc ^{[14
]}

Glusman, Edith Szafer ^{[15
]}

Lin, Jennifer ^{[15
]}

Dean, James P. ^{[15
]}

Neuenburg, Jutta K. ^{[15
]}

Tam, Constantine S. ^{[16
,17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[2] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[3] Gen Univ Hosp Prague, Prague, Czech Republic

[4] Charles Univ Prague, Dept Internal Med Haematol 4, Hosp & Fac Med, Hradec Kralove, Czech Republic

[5] Wroclaw Med Univ, Wroclaw, Poland

[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[8] Univ Med Ctr Groningen, Groningen, Netherlands

[9] Hosp Univ Cabuenes, Asturias, Spain

[10] Beth Israel Deaconess Med Ctr, Boston, MA USA

[11] Univ Paris, Hop St Louis, Assistance Publ Hop Paris, Serv Hematooncol, Paris, France

[12] Ctr Antoine Lacassagne, Nice, France

[13] CHU UCL Namur Mt Godinne, Yvoir, Belgium

[14] Univ Kansas, Ctr Canc, Kansas City, KS USA

[15] AbbVie, N Chicago, IL USA

[16] Alfred Hlth, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Monash Univ, Melbourne, Vic, Australia

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2023-191921

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA5 / LBA5

页数：1

共 50 条

[21] OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Le Gouill, Steven
Davies, Andrew
Bouabdallah, Kamal
Chiron, David
Rule, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
Wallace, Danielle S.
Rowland, Chris
Hill, Brian T.
Baran, Andrea M.
Casulo, Carla
Reagan, Patrick M.
Winter, Allison
Karmali, Reem
Winter, Jane N.
Gordon, Leo I.
Bui, Andrew
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Ma, Shuo
Barr, Paul M.
LEUKEMIA & LYMPHOMA, 2023,
[23] The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
Tam, Constantine Si Lun
Roberts, Andrew Warwick
Anderson, Mary Ann
Dawson, Sarah-Jane
Hicks, Rodney J.
Pott, Christiane
Westerman, David A.
Burke, Glenda
Kamel, Sarah
Dreyling, Martin H.
Dawson, Mark A.
Seymour, John Francis
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY
Tam, C.
Roberts, A.
Anderson, M. A.
Dawson, S. J.
Hicks, R.
Pott, C.
Westerman, D.
Burke, G.
Kamel, S.
Dreyling, M.
Dawson, M.
Seymour, J.
HAEMATOLOGICA, 2016, 101 : 103 - 103
[25] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
Baggio, Diva
Wellard, Cameron
Chung, Eliza
Talaulikar, Dipti
Keane, Colm
Opat, Stephen
Giri, Pratyush
Minson, Adrian
Cheah, Chan Yoon
Armytage, Tasman
Lee, Denise
Chong, Geoffrey
Johnston, Anna
Cochrane, Tara
Waters, Neil
Hamad, Nada
Wood, Erica M.
Hawkes, Eliza A.
LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
[26] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
Maruyama, Dai
Nagai, Hirokazu
Fukuhara, Noriko
Kitano, Toshiyuki
Ishikawa, Takayuki
Shibayama, Hirohiko
Choi, Ilseung
Hatake, Kiyohiko
Uchida, Toshiki
Nishikori, Momoko
Kinoshita, Tomohiro
Matsuno, Yoshihiro
Nishikawa, Tomoaki
Takahara, Satoko
Tobinai, Kensei
CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
[27] Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Balasubramanian, Sriram
Schaffer, Michael
Deraedt, William
Davis, Cuc
Stepanchick, Emily
Aquino, Regina
Yuan, Zhilong
Kranenburg, Britte
Avivi, Irit
Dreyling, Martin
Rule, Simon
Wang, Michael
Zhuang, Sen Hong
Rizo, Aleksandra
Lenz, Georg
BLOOD, 2014, 124 (21)
[28] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
Phillips, Tycel Jovelle
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Crump, Michael
Trneny, Marek
Bartlett, Nancy L.
Zaucha, Jan
Wrobel, Tomasz
Offner, Fritz
Humphrey, Kathryn
Relf, James
de L'Etang, Audrey Filezac
Carlile, David J.
Byrne, Ben
Qayum, Naseer
Lundberg, Linda
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
[29] A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
Qualls, David
Lam, Hiu Ying
Whiting, Karissa
Kumar, Anita
Matasar, Matthew
Owens, Colette
Nichols, Chelsea
Espeleta, James A.
Qiu, Annie
Subzwari, Sarima
Biggar, Erin
Seshan, Venkatraman
Salles, Gilles
Younes, Anas
Batlevi, Connie
BLOOD ADVANCES, 2022, 6 (18) : 5262 - 5266
[30] A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
Sawalha, Yazeed
Goyal, Subir
Switchenko, Jeffrey M.
Romancik, Jason T.
Kamdar, Manali
Greenwell, I. Brian
Hess, Brian T.
Isaac, Krista M.
Portell, Craig A.
Garcia, Alex Mejia
Goldsmith, Scott
Grover, Natalie S.
Riedel, Peter A.
Karmali, Reem
Burkart, Madelyn
Buege, Michael
Akhtar, Othman
Torka, Pallawi
Kumar, Anita
Hill, Brian T.
Kahl, Brad S.
Cohen, Jonathon B.
BLOOD ADVANCES, 2023, 7 (13) : 2983 - 2993

← 1 2 3 4 5 →